IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Trial Status: active
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Inclusion Criteria
- Pathology report confirming the diagnosis of B-cell PCNSL
- Relapsed or refractory B-cell PCNSL with at least 1 prior high-dose methotrexate (HD-MTX) based therapy for PCNSL:
- Relapsed disease: Participants who achieved a response (CR, CRu, PR) to the last treatment and subsequently experienced disease progression
- Refractory disease: Participants whose best response to the last treatment was stable disease or PD
- One or more measurable brain lesions with a diameter in at least one dimension greater than or equal to (≥) 1 centimeter (cm) in gadolinium-enhanced magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
- Adequate bone marrow, renal, and hepatic function per central lab values
- Participants must agree to comply with all defined contraceptive requirements
Exclusion Criteria
- Participants with isolated intraocular PCNSL or spinal PCNSL with no brain lesions
- Participants with non-B-cell PCNSL
- Participants with systemic presence of lymphoma
- Refractory to temozolomide with or without rituximab-containing regimens in the last PCNSL treatment
- Concomitant systemic corticosteroid exposure within 14 days before starting study drug per Investigator assessment with the exception of the following:
- Equivalent of up to 10 milligram per day (mg/day) of prednisone for a disease other than PCNSL
- Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day dexamethasone) for participants with lesions of the brain and/or spinal cord
- Active malignancy, other than PCNSL requiring systemic therapy
- Poorly controlled comorbidity, or history of medical conditions contraindicated per Investigator assessment
- Participants who are unable to swallow oral medication
- Prior Bruton's tyrosine kinase inhibitor treatment
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07104032.
Locations matching your search criteria
United States
Arizona
Scottsdale
Mayo Clinic in Arizona
Status: Approved
Name Not AvailableCalifornia
Orange
UC Irvine Health/Chao Family Comprehensive Cancer Center
Status: Active
Contact: Manisha Ajay Dandekar
Phone: 714-456-6221
Email: mdandeka@hs.uci.edu
Connecticut
New Haven
Yale University
Status: Active
Name Not AvailableDistrict of Columbia
Washington
Sibley Memorial Hospital
Status: Active
Name Not AvailableFlorida
Jacksonville
Mayo Clinic in Florida
Status: Approved
Name Not AvailableMaryland
Baltimore
University of Maryland/Greenebaum Cancer Center
Status: Active
Contact: Ben Kremenets
Phone: 410-328-7931
Email: Ben.Kremenets@umm.edu
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Active
Name Not AvailableBeth Israel Deaconess Medical Center
Status: Active
Name Not AvailableMassachusetts General Hospital Cancer Center
Status: Active
Name Not AvailableBrigham and Women's Hospital
Status: Active
Name Not AvailableMinnesota
Rochester
Mayo Clinic in Rochester
Status: Approved
Name Not AvailableNew Jersey
Hackensack
Hackensack University Medical Center
Status: Active
Name Not AvailableNew York
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not AvailableNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Status: Active
Name Not AvailableMemorial Sloan Kettering Cancer Center
Status: Active
Name Not AvailableRochester
University of Rochester
Status: Active
Name Not AvailableNorth Carolina
Charlotte
Carolinas Medical Center/Levine Cancer Institute
Status: Active
Name Not AvailableDurham
Duke University Medical Center
Status: Active
Name Not AvailableWinston-Salem
Wake Forest University Health Sciences
Status: Active
Name Not AvailablePennsylvania
Philadelphia
University of Pennsylvania/Abramson Cancer Center
Status: Active
Name Not AvailablePittsburgh
UPMC Hillman Cancer Center
Status: Active
Name Not AvailableWashington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Status: Active
Name Not AvailableTrial PhasePhase III
Trial Typetreatment
Lead OrganizationOno Pharmaceutical Co., Ltd.
- Primary IDONO-4059-17
- Secondary IDsNCI-2026-01488, 2025, 2025-523389-26-00
- ClinicalTrials.gov IDNCT07104032